Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
The contract development segment is expected to grow with a 15.8% CAGR during the analysis period, escalated by increasing demand for process optimization, route development, scale-up support, and technology transfer services as pharmaceutical companies advance next-generation obesity and metabolic disease therapies through clinical development
One new finding was a signal for dysesthesia a mild altered skin sensation that hadn't been seen in Phase 2 trials
No more app-switching." "The AI food scanner is scary accurate
NNMT overexpression is associated with obesity and insulin resistance
US$ 24.47
US$ 20.80
US$ 24.31
US$ 28.41
US$ 20.00
US$ 26.55
